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ABSTRACT 
The present work describes the synthesis of a novel series of heterocyclic moieties derived from 5-acetylpyrazolo[3,4-
b]pyridine (1). The formation of chalcones (2a-d) was utilized to synthesize pyrazoline, isoxazoline and pyrimidine 
derivatives (3-10). Thiosemicarbazone and semicarbazone (11, 17) were utilized to synthesize other new triazolethiones, 
thiadiazole and selenadiazole derivatives (11-19). Some new spiro derivatives (22-25) were synthesized by the reaction of 
chalcone (21) of 1 and isatine with hydrazines, hydroxyl amines and thiourea. Also, The reaction of 1 with cyanoacetyl 
hydrazine gave the hydrazide-hydrazone derivative 26, which was allowed to react with aromatic aldehydes and α-
cyanocinnamonitrile to afford coumarine and substituted pyridine derivatives (28, 29). The structures of all the new 
compounds have been established on the basis of their analytical and spectral data. Twenty two of the synthesized 
compounds were also evaluated for their antibacterial and antifungal activity against various strains of bacteria and fungi 
and most are found to possess promising antimicrobial activity when compared with Chloramphenicol  and Clotrimazole 
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INTRODUCTION  
The pyrazolo[3,4-b]pyridine  moieties  represent  important building blocks in both natural and synthetic bioactive  
compounds. 
1
 They are attractive targets in organic synthesis due to their significant biological activities such as xanthine 
oxidase inhibitors, cholesterol formation-inhibitor, and Anti-Alzheimer, 
2,3
 analgesic, 
4
 anxiolytic, 
5
 hypnotic, 
6
 antiviral, 
7
 
anti-HIV, 
8
 corticotropin-Releasing Factor (CRF) antagonist, 
9,10
 antidiabetic, 
11
  antiarrhythmic, 
12
  antitumor, 
13
 
antimalarial.  
14
  They also show antimicrobial and antiparasitic activities. 
15-17
 In addition, they are used as anti-HIV-1,
18
 as 
a potential glucocorticoid receptor ligand for positron emission tomography (PET). 
19
  It was found that some derivatives of  
pyrazolo[3,4-b]pyridine  were belived to be effective as antileishmanial agents, 
20
 inhibitors of erectile dysfunctions. 
21
 
Taking all the above into consideration and in continuation of our previous work directed to synthesis of new heterocycles 
engaged with pyrazole nuclei, 
22-25
 we describe herein the utilization of the 1-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-
b]pyridine-5-yl)ethanone (1) as the key intermediate in the synthesis of novel pyrazolo[3,4-b]pyridine members along with 
studies of the effect of some of them as antifungal and as antibacterial agents. 
RESULTS AND DISCUSSION 
The starting compound 2a-d were synthesized via the the Claisen-Schmidt reaction of 1-(3,6-dimethyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridine-5-yl)ethanone (1) 
26
 with different p-substituted aldehydes in ethanol and in presence of aqueous 
potassium hydroxide (25%). Presence of α-β-unsaturated keto function makes chalcones very prone to undergo reaction 
with bidentate nucleophiles to give five and six membered heterocyclic moieties. We intended to utilized this procedure to 
explore the formation of compounds 3-9 containing the pyrazole, isoxazole and pyrimidine rings linked on 5-position of 
pyrazolo[3,4-b]pyridine nucleus. Thus, cyclocondensation of chalcones 2c (R= Cl) with hydrazine hydrate or phenyl 
hydrazine in dry ethanol gave the corresponding pyrazole and N-phenylpyrazole derivatives 3a and 3b, respectively. The 
1
H NMR spectrum of compound 3a and 3b showed doublet of doublets of -CH2 near about δ 3.12-4.15 ppm  and doublet 
of doublets of –CH at δ 4.85-5.27 ppm, confirmed the cyclisation in pyrazoline. Also, the reaction of 2c with 
hydroxylaminehydrochloride in the presence of anhydrous sodium acetate led to the formation of 5-[5-(4-chlorophenyl)-
4,5-dihydro-1,2-isoxazol-3-yl]-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (4). The IR spectra of 4 clearly showed the 
formation of isoxazoline ring by the appearance of band at 1509 cm
-I
 for (=C=N-O). 
1
H NMR data also confirmed the 
synthesis by showing a doublet at δ 3.75 ppm for 2H and a triplet at δ 4.40 ppm for 1H of  isoxazoline ring. Similarly, the 
reaction of 2c with urea and/or thiourea in presence of aqueous potassium hydroxide (10%) gave the corresponding 
pyrimidinone and thiopyrimdine derivatives (5a, b) respectively. S-alkylated products (6a,b) were obtained upon treatment 
of 5b with ethyl iodide and benzyl bromide in the presence of anhydrous sodium acetate in refluxing ethanol.  Moreover, 
treatment of 2c with guanidine hydrochloride in dry ethanol containing sodium hydroxide solution(10%) yielded 2-Amino-4-
(4-chlorophenyl)-6-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrimidine
 
(7). Heating of 7 with benzaldehyde in 
refluxing methanol in the presence of few drops of acetic acid resulted in the formation of the corresponding Schiff base 
(8). Condensation of chalcones with thiosemicarbazide has  became an extremely popular method for making pyrazoline 
derivatives. Thus, treatment of 2c with thiosemicarbazide in an ethanolic sodium hydroxide solution,yielded the pyrazole 
carbothioamide (9).The IR spectra of compound 9 showed intense bands at 3425, 3250, 1580 and 1370 cm
-1
 due to NH2, 
C=N and C=S groups, respectively. In addition, the absorption band at 1120 cm
-1
 was attributed to the C-N, which also 
confirm the formation of desired pyrazoline ring. In the 
1 
HNMR spectra, pyrazoline protons HA and HB are germinal 
protons at C4 carbon appears at 3.46 and 4.0 ppm as doublet of doublets. The CH proton also appeared as doublet of 
doublets at 5.15 ppm due to vicinal coupling with two non-equivalent germinal protons of C4 carbon. Compound 9 
underwent ready  cyclization upon treatment with α-haloketones  in the presence of anhydrous sodium acetate to afford 5-
(4-Chlorophenyl)-4,5-dihydro-1-(4-substitutedthiazol-2-yl)-1-H-pyrazol-3-yl)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-
b]pyridines (10a,b) (Scheme 1).  On the other hand, condensation of the target compound (1) in boiling ethanol with 
thiosemicarbazide afforded the corresponding thiosemicarbazone (11), 
27
 which was allowed to react with α-haloketones  
to yield the corresponding thiazolidines derivatives (12a,b). In addition, the thiosemicarbazone (11) was heated with 
methanolic HCl to give 5-methyl-5-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-1,2,4-triazolidine-3-thione (13). 
A further support for the structure of (13) was achieved by synthesis of the compound via another route by boiling a 
solution of 1 in methanolic HCl. All of spectral analyses completely identical and confirmed the formation of compound 13 
by the two routes. We have observed that extensive thiol-thione tautomerism exists in compound 13. In most cases of 
nucleophilic substitution of an alkyl halide on a thioamide system, sulfur atom \attack is favored. 
28
 Thus, treatment of 13 
with 1-bromo-2-methoxyethane in warm DMF in the presence of potassium carbonate afforded the desired products 14 
and 15. Column chromatography of the crude material was allowed of the isolation of both isomers. The S-alkylation 
product 14 as a major (79% yield) and the other N-alkylation product 15 (14.8% yield). 
1
HNMR and 
13
CNMR spectra of the 
synthesized compounds provided proof of the S- and N-alkylated triazoles 14 and 15, respectively. The CH2 protons 
adjacent to the sulfur atom  in compound 14 appears at 3.75 ppm and the carbon resonates at 33.6 ppm. However, CH2 
protons adjacent to the nitrogen atom in compound 15 are more download-shifted to 4.60 and the carbon resonates at 
46.27 ppm. Finally, the 
13
CNMR spectra show peak at 172 ppm corresponding to the C=S group associated with  the N- 
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Scheme 1   Pathway for synthesis of compounds 2-10 
 
alkylated derivative 15, whereas the S-alkylated derivative 14 gave peak at 152 ppm  for the same carbon corresponding 
to C-S group. Also, compound 13 was allowed to react with N-phenyl maleimide in acetic acid to afford 2-[2-(3,6-dimethyl-
1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-2-methyl-6-oxo-1,2,5,6-tetrahydro-[1,3]thiazolo[3,2-b][1,2,4]triazol-5-yl]-N-
phenyl-cetamide (16). The IR spectra of thiazolotriazole (16) showed the absorption bands at 1710 and 1585 cm
-1
 
corresponding to C=O and C=N, respectively. In the 
1
H NMR spectra of compound 16, protons of CH2-CH fragment 
showed the characteristic patern of an ABX system. The chemical shifts of the protons HA, HB and HX are doublet of 
doublets at 2.8, 3.3and at 4.6 ppm, respectively. The acetamide NH proton appeared at a sharp singlet at 13.30 ppm. In 
addition, the 
13
C CNMR spectra displayed characteristic two singlets at 173.25 and 178.85 ppm due to the acetamide 
carbamoyl carbon(CONH) and the thiazolidinone carbonyl carbon(CO-N-), respectively.  Condensation of  the  target  
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compound  4-acetyl-3-methyl-5-oxo-1-phenyl-2-pyrazoline  (1)  in  boiling  ethanol  with semicarbazide  hydrochloride  
afforded  the  corresponding  semicarbazone  (17). When the semicarbazone  17 was reacted with thionyl chloride it gave 
4-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-yl)-1,2,3-thiadiazole (18). On the other hand, treatment of 17 with selenium 
dioxide, 4-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-yl)-1,2,3-selenadiazole (19) was obtained. Structure of compounds 18 
and 19 was supported in the basis of elemental and spectral analysis.  FT-IR  spectra  exhibited  the  absence  of  (NH)  
and  (NH2) absorption bands of the semicarbazone and revealed a characteristic absorption band at 820 cm
-1
 due to C-
Se-N. 
29
 
1
HNMR spectra also appeared two singlets at δ 9.75 and 10.12 ppm corresponding to the CH protons of 
thiaziazole and selenadiazole, respectively (Scheme 2).  
 
 
1
NH2NHCSNH2
EtOH
N
N
Ph
N
H3C
CH3
NNHCSNH2
CH3
NH2NHCONH2.HCl
AcONa / EtOH
N
N
Ph
N
H3C
CH3
NNHCONH2
CH3
NaOAc/ EtOH
N
N
Ph
N
H3C
CH3
N
CH3
NH
S
N
R
a, R = CH3
b, R = C6H5
SeO2
AcOH
N
N
Ph
N
H3C
CH3
N
N
Se
N
N
Ph
N
H3C
CH3
N
N
S
N
N
Ph
N
H3C
CH3
MeOH/HCl
SOCl2
11
12a,b
17
18 19
14
N
H
NHHN
H3C
S
N
N
Ph
N
H3C
CH3
13
N
H
NHN
H3C
SH
(i) NH2NHCSNH2
(ii) MeOH/ HCl
N
N
Ph
N
H3C
CH3
N
H
NHN
H3C
S O
Br
O
+
15
N
N
Ph
N
H3C
CH3
N
H
NHN
H3C
S
O
79% yield 14.8% yield
RCOCH2X
N
O
O
AcOH
N
N
Ph
N
H3C
CH3
N
NHN
H3C S
O
H
N
O
16
K2CO3 / DMF
 
Scheme 2   Pathway for synthesis of compounds 11-19 
 
Crossed aldol condensation between 5-acetylpyrazolo[3,4-b]pyridine (1) and isatin was carried out in the presence of 
diethyl amine as a basic catalyst gave rise the formation of  3-hydroxy-3-(2-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-
b]pyridine-5-yl)-2-oxoethyl)indolin-2-one (20). Dehydration of 20 using Ethanol-HCl mixture afforded the corresponding 
chalcone 21. Nucleophilic Michael addition of hydrazine hydrate to the chalcone 21 gave spiropyrazoline derivative (22) 
(method A). Moreover, spiropyrazoline (22) was obtained in an excellent yield via a one-pot synthesis without the isolation 
of the intermediate 21. Thus, compound 1 reacted with isatin in the presence of diethylamine for 30 min at room 
temperature and the formed solid was treated with glacial acetic acid and hydrochloric acid for another 30 min at 80 C. 
Hydrazine hydrate was then added to the previous acidic solution to give the spiropyrazoline (22) (method B). The 
chalcone derivative (21) when interacted with phenylhdyrazine in ethanol as solvent, gave the required spiro N-
    ISSN 2321-807X 
2905 | P a g e                                                      O c t o b e r  1 4 ,  2 0 1 4  
phenylpyrazoline derivative (23). 3′-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-4′-dihydrospiro[indol-3,5′-
isoxazole]-2-(1H)-one (24) was obtained by the refluxing of the chalcone 21 with hydroxylamine hydrochloride in ethanol in 
the presence of sodium acetate as catalyst. Also, compound 21 was interacted with thiourea in ethanol as solvent and in 
the presence of potassium hydroxide, gave the 6′-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)- spiro[indol-3,4′ -
pyrimidin-2′- (1H) thione]-2-(1H)-one (25) (Scheme 3).  
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Scheme 3   Pathway for synthesis of compounds 20-25 
 
1
HNMR spectra confirmed the formation of the chalcone (21) by the absence of a peak at δ 3.15 ppm corresponding to 
CH2 protons in the aldol product (20). 
1
HNMR spectra of the spiropyrazoline (22) revealed the presence of the 
characteristic peaks at δ 3.65, 6.30 and 8.63 ppm due to CH2 protons of  pyrazoline and NH protons of each pyrazoline 
and indoline moieties, respectively.  The structure of 25 was indicated by spectral methods, its IR spectra revealed 
characteristic bands at 3340, 3210, 3180 and 1180 cm
-1
 corresponding to (NH) and (C=S), respectively. The 1 HNMR 
spectra of 25 showed the presence of two broad exchangeable singlets at δ 8.85 and 9.90 ppm for two NH protons of 
pyrimidine ring. With the aim of obtaining novel hydrazide-hydrazone with a wide spectrum of pharmaceutical applications, 
30
 we report herein the reaction of 5-acetylpyrazolo[3,4-b]pyridine (1)  with cyanoacetyl hydrazine in dioxane to yield the 
corresponding acetohydrazide-hydrazine derivative (26). The structure of  compound 26 was confirmed based on its 
analytical and spectral data. Thus, the 1H-NMR showed a singlet at δ 4.40 for the CH2 group and a singlet (D2O 
exchangeable) at δ10.95 for the NH group. Moreover, the 
13
C- NMR spectrum showed peaks at δ 12.90, 26.80, 113.64 
and  174.19 ppm corresponding to (CH3), (CH2), (CN) and (C=O), resoectively. Further structure elucidation of compound 
26 was obtained through the study of its reactivity towards chemical reagents. Thus, reaction of 26 with p-
chlorobenzaldehyde gave the corresponding benzal derivative (27). On the other hand, the coumarin derivative (28) was 
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obtained via the reaction of 26 with salicyladehyde . Finally, the reaction of 26 with α-cyanocinnamonitrile gave 6-amino-1-
[1-(3,6- dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)ethylideneamino]-2-oxo-4-phenyl-1,2-dihydropyridine-3,5-
dicarbonitrile (29). The structure of 29 was confirmed by spectral and analytical data. Thus, The IR spectra revealed the 
presence of absorption bands at 3452, 3368, 2229 and 2189 cm
-1
 due to NH2 and two CN functions, respectively. ( 
Scheme 4). 
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 Scheme 4   Pathway for synthesis of compounds 26-29 
Antimicrobial Activity 
The antimicrobial activity of 22 selected compounds was screened against bacterial strains Staphylococcus aureus 
(AUMC B.54),  Bacillus cereus (AUMC B.52) as gram-positive bacteria and  Escherichia coli (AUMC B.53), Pseudomonas 
aeruginosa (AUMC B.73) as gram-negative bacteria and fungal strains Candida albicans (AUMC No.214), Aspergillus 
flavus (AUMC No.1276) using the agar well-diffusion method. 
31 The screening tests were carried out in triplicate and the 
results were expressed as a mean of three determinations. Chloramphenicol and Clotrimazole were used as standards. 
Data are represented as % inhibition with reference to standards in (Table1). The results obtained from table 1 revealed 
that a comparison of the antimicrobial activity of the chalcone derivatives (2a-d), indicated that the para-chloro derivative 
2c induced more activity against all of the tested microorganisms (76 - ›100% growth inhibition). The 5-isoxazolinyl 
derivative 4 was more potent than the 5-pyrazolinyl derivative 3a and showed a good antifungal activity only against C. 
albicans (89% growth inhibition) and A. flavus (79% growth inhibition). The 5- pyrimidinylthione compound 5b (R= CH2Ph) 
showed a remarkable antimicrobial activity towards all of gram-positive bacteria (›100% growth inhibition against 
S.aureus) and also exhibited an excellent antifungal activity against C. albicans  (›100% growth inhibition). Formation of 
Schiff base of 5-aminopyrimidinyl derivative with benzaldehyde compound 8 showed only ›100% growth inhibition against 
C. albicans which was comparable to clotrimazole .The N-thiazolylpyrazolinyl derivative 10a(R= CH3) showed a 
remarkable antibacterial activity against gram-negative bacteria species E.coli (›100% growth inhibition) and P. 
aeruoginosa (83% growth inhibition) and also exhibited a strong antifungal activity against C. albicans (›100% growth 
inhibition). While, its phenyl isomer 10b (R= Ph) was inactive towards most of the tested microorganisms. Similarly, the N-
phenyl thiazolylhydrazine derivative 12b (R=Ph) did not show any activity against all of tested bacteria and fungi species. 
Whereas, it's N-methyl derivative 12a (R=CH3) showed an excellent antimicrobial activity against all of tested bacteria and 
fungi species except P. aeruoginosa (95% growth inhibition against E.coli). Building up a new 1,2,4-triazolidine thione 
compound 13 showed ›100% growth inhibition activity against all of tested bacteria and fungi species except P. 
aeruoginosa. The S-alkylating product compound 14 exihibited only 86% growth inhibition against E.coli.  The creation of a 
novel thiazolotriazole ring compound 16, enhanced the antimicrobial activity.  
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Table 1: Antimicrobial activity of some pyrazolo[3,4-b]pyridine derivatives 
Compounds Diameter of zone of inhibition (mm) / % inhibition with reference to standard
*
 
   Gram-positive bacteria        Gram- nagative bacteria                          Fungi 
   S.aureus        B.cereus         E.coli          P.aeruoginosa     C.albicans       A. flavus    
2a 
2b                                                  
- 
-
10(40) 
8(32)        
9 (43) 
- 
- 
- 
8 (30 ) 
- 
- 
- 
2c 
2d 
17(85 ) 
- 
 19(76 ) 
- 
- 
- 
16(89 ) 
- 
34(›100) 
6(22) 
35(92 ) 
- 
3a - - - - 7(26) - 
4 - - - -    24(89 ) 30(79 ) 
5a - - - - 9 (33) - 
5b 26(›100) 21(84 ) - - 31(›100 ) - 
8 - - 11(52 ) - 29(›100 ) 23(61) 
10a - - 25(›100) 15(83 ) 30(›100 ) 26(68 ) 
10b - - - - - 12(32 ) 
12a 18(90) 20(80) 20(95 ) - 23(85) 30(79) 
12b - - - - - - 
13 25(›100) 24(96) 28(›100) - 32(›100) 41(›100) 
14 - - 18(86) - - - 
16 
18 
14(70)             
22(›100) 
22(88) 
19(76 ) 
- 
24(›100) 
- 
- 
31(›100) 
- 
36(95) 
32(84) 
19 - - - - 29(›100)    40(›100) 
22 8(40) - - - 11(41) 10(26) 
24 - - - - - - 
25 - - 28(›100) 16(89 ) 30(›100) - 
28 - - - - - - 
Chloramphenicol 
Clotrimazole 
20(100) 
- 
25(100) 
- 
21(100) 
- 
18(100) 
- 
- 
27(100) 
- 
      38(100) 
*The percentage zone of inhibition was calculated against the bacterial and fungal strains. Solvent and negative 
         control: DMSO (dimethylsulfoxide)- No inhibition observed         
 
Thus, compound 16 showed a significant antibacterial activity against gram-positive only (88% growth inhibition against 
B.cereus) and also exhibited an excellent antifungal activity (›100% growth inhibition against C. albicans).  On the other 
hand, the comparison of the percentage of growth inhibition of the thiadiazole and selenadiazole 18 and 19 respectively, 
demonstrated that thiadiazole derivative 18 is more potent against all of tested bacteria and fungi species except P. 
aeruoginosa and C. albicans (›100% growth inhibition against S.aureus and E.coli ), while, the selenadiazole 19 showed 
only an excellent antifungal activity (›100% growth inhibition against C. albicans and A. flavus). Among all of the 
spiroindolyl derivatives 22, 24 and 25 only, the spiroindolylpyrimidinethione 25 showed a significant antibacterial activity 
against gram-negative species (›100% growth inhibition against E.coli) and also exhibited ›100% growth inhibition against 
C. albicans. With respect to the formation of coumarin compound 28, it was devoid of growth inhibition against all of the 
tested microorganisms.   
CONCLUSION  
The present study research study reports the convienent synthesis, reactions and antimicrobial activity of a new series of 
pyrazolo[3,4-b]pyridines carrying biologically active heterocyclic entities. Their Screening results revealed that most of the 
tested compounds showed a remarkable to an excellent activities and might be helpful in the future development of 
pyrazolopyridines as analogues as a novel antimicrobial agents. 
    ISSN 2321-807X 
2908 | P a g e                                                      O c t o b e r  1 4 ,  2 0 1 4  
EXPERIMENTAL 
Melting points are uncorrected and determined using a Gallenkamp melting point apparatus. IR spectra were recorded on 
a Pye-Unicam SP 3-100 spectrophotometer using the KBr wafer technique. 
1
H NMR spectra were recorded on a Varian 
EM-390 90 MHz spectrometer and on GNM-LA (400 MHz) in DMSO-d6 as solvent and TMS as internal standard. 
Chemical shifts are expressed in ppm. 
13
C NMR spectra were measured on a Varian EM-200, 100 MHZ spectrometer.  
Mass spectra were determined on a JEOL JMS-600 spectrometer. Elemental analyses were carried out at the 
Microanalytical Unit at the at Assiut University (Egypt). Compounds 1 was prepared according to literature procedure. 
26
 
Compounds 2a, 11 and 17 were prepared were prepared as previously reported.
27
 
General procedure for the synthesis of 1-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-3- 
substitutedphenylprop-2-en-1-one (2a-d). 
A mixture of 1 (0.002 mol), appropriate aromatic aldehydes (0.00 2 mol) and potassium hydroxide solution (5 mL, 25%) in 
ethanol (25 mL) was stirred overnight. The product was filtered off, washed with water, dried and crystallized from ethanol. 
 
1-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (2b) 
A yellow crystals, 56%, mp 134-136ºC. FT-IR (KBr) νmax/ cm
-1
: 3062 (CH- aromatic), 2985, 2930 (CH- aliphatic), 1682 
(C=O), 1585 (C=N), 1439 (C=C), 1070 (C-O); 
1
H NMR δ 2.40 (s, 3H, CH3), 2.55 (s, 3H, CH3), 3.85 (s, 3H, OCH3), 6.75 (s, 
1H, CH-ethylenic), 7.50-8.35 (m, 12H, 9H-aromatic + 1H, CH-ethylenic + 1H, CH-pyridine), Anal. Calcd for 
C24H21N3O2(383.44): C, 75.18; H, 5.52; N,10.96. Found: C, 75.51; H, 5.88; N, 11.25%. 
  
1-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(4-chlorophenyl)prop-2-en-1-one (2c) 
A yellow crystals, 83%, mp 188-190ºC. FT-IR (KBr) νmax/ cm
-1
: 3080(CH- aromatic), 2980, 2866(CH- aliphatic), 1690 
(C=O), 1570 (C=N), 1490 (C=C); 
1
H NMR δ 2.45 (s, 3H, CH3), 2.68 (s, 3H, CH3), 6.63 (s, 1H, CH-ethylenic), 7.50-8.30 (m, 
12H,10H-aromatic + 1H, CH-ethylenic + 1H, CH-pyridine), Anal. Calcd. for C23H18ClN3O(387.86): C, 71.22; H, 4.68; Cl, 
9.14;  N, 10.83. Found: C, 71.48; H, 5.02; Cl, 9.37; N, 11.11%. 
 
1-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(4-nitrophenyl)prop-2-en-1-one (2d)  
A yellow crystals, 69%, mp 208-210ºC. FT-IR (KBr) νmax/ cm
-1
: 3097 (CH- aromatic), 2953, 2880 (CH- aliphatic), 1678 
(C=O), 1565 (C=N), 1469 (C=C); 
1
H NMR δ 2.40 (s, 3H, CH3), 2.70 (s, 3H, CH3), 6.48 (s, 1H, CH-ethylenic), 7.40-8.55 (m, 
12H,10H-aromatic + 1H, CH-ethylenic + 1H, CH-pyridine), Anal. Calcd. for C23H18N4O3(398.41): C, 69.34; H, 4.55; N, 
14.06. Found: C, 69.59; H, 4.84; N, 14.30%. 
 
General procedure for the synthesis of 5-[5-(4-chloro phenyl)-3,6-dimethyl--4,5-dihydro-1H (phenyl)-pyrazol-3-yl]-
1-phenyl-1H-pyrazolo[3,4-b]pyridine (3a,b) 
A mixture of chalcone 2c (0.001 mol), hydrazine hydrate or phenyl hydrazine (0.001mol) was heated under reflux for 4 h, 
in 20 mL ethanol then cooled and the residual material was filtered off and recrystallized from ethanol.  
 
5-[5-(4-chlorophenyl)-3,6-dimethyl--4,5-dihydro-1H-pyrazol-3-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine (3a) 
A yellow crystals, 66%, mp 159-161ºC. FT-IR (KBr) νmax/ cm
-1
: 3100 (NH), 3020 (CH- aromatic), 2980 (CH- aliphatic), 
1530 (C=N), 1440(C=C); 
1
H NMR δ 2.48 (s, 3H, CH3), 2.66 (s, 3H, CH3), 3.12(dd, J1=4.75 Hz, J2= 7.70, 1H, CH2-
pyrazoline), 4.21(dd, J1=3.80 Hz, J2= 8.20, 1H, CH2-pyrazoline), 4.85 (dd, J1=1.60 Hz, J2= 8.90, 1H, CH-pyrazoline) 7.70- 
8.45 (m, 11H, 10H-aromatic + 1H, CH-pyridine), 8.80 (s, 1H, NH); MS m/z (%): 401.46 (M
+
, 100); Anal. Calcd. for 
C23H20ClN5 (401.89): C, 68.74; H, 5.02; Cl, 8.82; N, 17.43. Found: C, 69.03; H, 5.38; Cl, 9.13;  N, 17.70%. 
 
5-[5-(4-Chlorophenyl)-3,6-dimethyl--4,5-dihydro-1-phenylpyrazol-3-yl]-1-phenyl-1H-pyrazolo[3,4-b]pyridine (3b) 
A yellow crystals, 71%, mp 223-225ºC. FT-IR (KBr) νmax/ cm
-1
: 3066 (CH- aromatic), 2969 (CH- aloiphatic), 1546 (C=N), 
1481 (C=C); 
1
H NMR δ 2.55 (s, 3H, CH3), 2.69 (s, 3H, CH3), 3.25 (dd, J1=5.30 Hz, J2= 2.70, 1H, CH2-pyrazoline), 4.15 (dd, 
J1= 3.60 Hz, J2= 1.80, 1H, CH2-pyrazoline), 5.27(dd, J1=8.40 Hz, J2= 1.20, 1H, CH-pyrazoline) 7.65-8.55 (m, 15H, 14H-
aromatic + 1H, CH-pyridine); Anal. Calcd. for C29H24ClN5 (477.99): C, 72.87; H, 5.06; Cl, 7.42; N, 14.65. Found: C, 73.12; 
H, 5.33; Cl, 7.65;  N, 14.84%. 
5-[5-(4-chlorophenyl)-4,5-dihydro-1,2-isoxazol-3-yl]-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (4) 
A mixture of chalcone 2c (0.38 g, 0.001 mol), hydroxylamine hydrochloride (0.07g, 0.001 mol) and anhydrous sodium 
acetate (1 g) was refluxed in ethanol (20 mL) for 6h, then allowed to cool and poured into cold water. The precipitated 
product thus formed was collected by filtration, dried and recrystallized from methanol to give compound 4 as yellow 
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crystals, 68%, mp 165-167ºC. FT-IR (KBr) νmax/ cm
-1
: 3078 (CH- aromatic), 2965 (CH- aliphatic), 1620 (C=N), 1540 (C=C), 
1509 (=C=N-O); 
1
H NMR δ 2.37 (s, 3H, CH3), 2.64 (s, 3H, CH3), 3.15 (dd, J1=5.30 Hz, J2= 2.70, 1H, CH2- isoxazol), 3.78 
(dd, J1= 3.60 Hz, J2= 1.80, 1H, CH2- isoxazol), 5.15 (dd, J1=8.40 Hz, J2= 1.20, 1H, CH- isoxazol) 7.65-8.55 (m, 15H, 14H-
aromatic + 1H, CH-pyridine); Anal. Calcd. for C29H24ClN5 (477.99): C, 72.87; H, 5.06; Cl, 7.42; N, 14.65. Found: C, 73.12; 
H, 5.33; Cl, 7.65;  N, 14.84%. 
General procedure for the synthesis of 4-(4-chlorophenyl)-6-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-
yl)pyrimidin-2-ol (thiol) (5a,b) 
A mixture of chalcone 2c (0.02 mol), urea or thiourea (0.02 mol) were dissolved in ethanolic sodium hydroxide (5%, 10 
mL) was stirred about 2-3 hours with a magnetic stirrer. This was then poured into 400 ml of cold water with continuous 
stirring for an hour and then kept in refrigerator for 24 hours. The precipitate obtained was filtered, washed and 
recrystallized ethanol.  
 
4-(4-chlorophenyl)-6-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-ol (5a) 
A  pale brown crystals, 71%, mp 236-238ºC. FT-IR (KBr) νmax/ cm
-1
: 3460 (OH), 3060 (CH- aromatic), 2982 (CH- aliphatic), 
1606 (C=N), 1472 (C=C); 
1
H NMR δ 2.61 (s, 3H, CH3), 2.74 (s, 3H, CH3), 3.20 (s, 1H, OH), 7.25 (s, 1H, CH-pyrimidine), 
7.55-8.60 (m, 10H, 9H-aromatic + 1H, CH-pyridine); Anal. Calcd. for C24H18ClN5O (427.89): C, 67.37; H, 4.24; Cl, 8.29; N, 
16.37. Found: C, 67.71; H, 4.48; Cl, 8.52;  N, 16.39%. 
 
4-(4-chlorophenyl)-6-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-thiol (5b) 
A  pale brown crystals, 79%, mp 293-295ºC. FT-IR (KBr) νmax/ cm
-1
: 3372, 3267 (NH), 3061 (CH- aromatic), 2995 (CH- 
aliphatic), 1626 (C=N), 1375 (C=S); 
1
H NMR δ 2.55 (s, 3H, CH3), 2.79 (s, 3H, CH3), 3.40 (s, 1H, SH), 7.50-8.54 (m, 11H, 
9H-aromatic + 1H, CH-pyridine + 1H, CH- pyrimidine); Anal. Calcd. for C24H18ClN5S (443.95): C, 64.93; H, 4.09; Cl, 7.99; 
N, 15.78; S, 7.22%. Found: C, 65.28; H, 4.24; Cl, 8.30;  N, 16.07; S, 7.53%. 
 
General procedure for the synthesis of 2-substituted thio-4-(4-chlorophenyl)-6-(3,6-dimethyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridin-5-yl)pyrimidine (6a,b) 
 A mixture of 5b (0.01 mol), ethyl iodide or benzyl bromide (0.01 mol) in ethanol (40 mL) was refluxed in the presence of 
anhydrous sodium acetate (0.9 g, 0.011 mol) for 4 h. The solid product separated from the hot mixture was filtered off, 
washed with water and recrystallized from ethanol 
 
 4-(4-Chlorophenyl)-2-ethylthio-4-(4-chlorophenyl)-6-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrimidine (6a) 
A pale yellow crystal, 68%, mp 167-169ºC. FT-IR (KBr) νmax/ cm
-1
: 3088 (CH- aromatic), 2975 (CH-aliphatic), 1620 (C=N), 
1498 (C=C), 1266 (C-S); 
1
H NMR δ 1.25 (t, 3H, SCH2-CH3), 2.45 (s, 3H, CH3), 2.60 (s, 3H, CH3), 4.00 (q, 2H, SCH2CH3), 
7.40 (s, 1H, CH-pyrimidine), 7.60-8.75 (m, 10H, 9H-aromatic + 1H, CH-pyridine); Anal. Calcd. for C26H22ClN5S (472.13): 
C, 66.16; H, 4.70; Cl, 5.71; N, 14.84; S, 6.79. Found: C, 66.48; H, 5.06; Cl, 5.82; N, 15.13; S, 7.12%. 
 
2-Benzylthio-4-(4-chlorophenyl)-6-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrimidine (6b) 
A  pale yellow crystals, 61%, mp 157-159ºC. FT-IR (KBr) νmax/ cm
-1
: 3090 (CH- aromatic), 2874 (CH- aliphatic), 1615 
(C=N), 1398 (C=C), 1244 (C-S); 
1
H NMR δ 2.40 (s, 3H, CH3), 2.65 (s, 3H, CH3), 4.15 (s, 2H, SCH2Ph), 7.35 (s, 1H, CH-
pyrimidine), 7.55-8.60 (m, 16H, 15H-aromatic + 1H, CH-pyridine); Anal. Calcd. for C31H24ClN5S (534.07): C, 69.72; H, 
4.53; Cl, 6.64; N, 13.11; S, 6.00. Found: C, 66.93; H, 5.00; Cl, 6.77; N, 13.39; S, 6.21%. 
 
2-Amino-4-(4-chlorophenyl)-6-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrimidine (7) 
A mixture of chalcone 2c (0.76 g, 0.002 mol), guanidine hydrochloride (0.19 g, 0.002 mol) and ethanolic sodium hydroxide 
(10%, 10mL) was refluxed for 2–3 h. After cooling, the solid formed was filtered off, air dried and recrystallized from 
absolute ethanol to give compound 7 as brown crystals, 71%, mp 305-307ºC. FT-IR (KBr) νmax/ cm
-1
: 3320, 3290 (NH2), 
3035 (CH- aromatic), 2880 (CH- aliphatic), 1627 (C=N), 1526 (C=C); 
1
H NMR δ 2.54 (s, 3H, CH3), 2.63 (s, 3H, CH3), 6.95 
(s, 1H, CH-pyrimidine), 7.55-8.45 (m, 10H, 9H-aromatic + 1H, CH-pyridine), 9.45 (s, 2H, NH2, D2O exchangeable); Anal. 
Calcd. for C24H19ClN6 (426.9): C, 67.52; H, 4.49; Cl, 8.30; N, 19.69. Found: C, 67.83; H, 4.79; Cl, 8.60;  N, 19.77%. 
2-(4-Chlorobenzylideneamino)-4-(4-chlorophenyl)-6-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5- 
yl)pyrimidine (8) 
A mixture of compound 7 (0.43 g, 0.001 mol) and benzaldehyde (0.11 g, 0.001 mol) was stirred under reflux in methanol 
(30 ml) in the presence of a few drops of glacial acetic acid for 5 h. The reaction mixture was allowed to cool to room 
temperature, poured into water, whereby a solid formed that was filtered off and crystallized from dioxane to give 
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compound 8 as brown crystals, 68%, mp 263-265ºC. FT-IR (KBr) νmax/ cm
-1
: 3018(CH- aromatic), 2890 (CH- aliphatic), 
1633 (C=N), 1525 (C=C); 
1
H NMR δ 2.48(s, 3H, CH3), 2.70 (s, 3H, CH3), 7.35-8.35 (m, 17H, 14H-aromatic + 1H, CH-
pyridine + 1H, CH-pyrimidine + 1H, CH=N); Anal. Calcd. for C31H23ClN6 (515.01): C, 72.30; H, 4.50; Cl, 6.88; N, 16.32. 
Found: C, 72.58; H, 4.90; Cl, 7.10;  N, 16.62%. 
5-(4-Chlorophenyl)-4,5-dihydro-3-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazole-1- 
carbothioamide (9) 
A mixture chalcone 2c (0.76 g, 0.002 mol) and thiosemicarbazide (0.18 g, 0.001 mol)  in and ethanolic sodium hydroxide 
(25%, 10 mL) was refluxed for 3 h.The reaction mixture was allowed to cool to room temperature, whereby a solid formed 
that was filtered off and crystallized from DMF-H2O to give compound 9 as yellow crystals, 70%, mp 202-204ºC. FT-IR 
(KBr) νmax/ cm
-1
: 3425, 3250 (NH2), 3057 (CH- aromatic), 2927 (CH- aliphatic), 1580 (C=N), 1460 (C=C), 1370 (C=S), 
1120 (C-N); 
1
H NMR δ 2.52 (s, 3H, CH3), 2.70 (s, 3H, CH3), 3.46(dd, J1=4.59 Hz, J2= 8.25, 1H, CH2-pyrazoline), 4.0(dd, 
J1=4.68 Hz, J2= 8.45, 1H, CH2-pyrazoline), 5.15 (dd, J1=1.68 Hz, J2= 8.85, 1H, CH-pyrazoline), 6.70 (s, 1H, NH2); 7.45- 
8.30 (m, 10H, 9H-aromatic + 1H, CH-pyridine); Anal. Calcd. for C24H21ClN6S (460.98): C, 62.53; H, 4.59; Cl, 7.69; N, 
18.23; S, 6.96. Found: C, 62.82; H, 5.01; Cl, 8.01;  N, 18.47; S, 7.16%; MS m/z (%): 460.42 (M
+
, 76). 
General procedure for the synthesis of 5-(4-Chlorophenyl)-4,5-dihydro-1-(4-substitutedthiazol-2-yl)-1-H-pyrazol-3-
yl)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridines (10a,b) 
A mixture of 9 (0.01 mol), chloroacetone or phenacyl bromide (0.01 mol) in ethanol (50 mL) was refluxed in the presence 
of anhydrous sodium acetate (0.9 g, 0.011 mol) for 4 h. The solid product separated from the hot mixture was filtered off, 
washed with water and recrystallized from the proper solvent.  
 
5-(4-Chlorophenyl)-4,5-dihydro-1-(4-methylthiazol-2-yl)-1-H-pyrazol-3-yl)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
(10a). 
 A yellow crystals (EtOH), 70%, mp 325-327ºC. FT-IR (KBr) νmax/ cm
-1
: 3066 (CH- aromatic), 2947 (CH- aliphatic), 1626 
(C=N), 1562 (C=C);
1
H NMR δ 2.55 (s, 3H, CH3), 2.77 (s, 3H, CH3), 3.19(dd, J1=5.22 Hz, J2= 7.35, 1H, CH2-pyrazoline), 
3.65 (dd, J1=3.75 Hz, J2= 9.31, 1H, CH2-pyrazoline), 4.75 (dd, J1=1.45 Hz, J2= 8.52, 1H, CH-pyrazoline),  6.45 ( s, 1H, CH-
thiazole); 7.30- 8.47 (m, 10H, 9H-aromatic + 1H, CH-pyridine). Anal. Calcd. for C27H23ClN6S (499.03): C, 64.98; H, 4.65; 
Cl, 7.10; N, 16.84; S, 6.43. Found: C, 65.12; H, 4.98; Cl, 7.38;  N, 17.09; S, 6.49%. 
 
5-(4-Chlorophenyl)-4,5-dihydro-1-(4-phenylthiazol-2-yl)-1-H-pyrazol-3-yl)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-
b]pyridines (10b) 
A yellow crystals (Dioxane),71%, mp 217-219ºC. FT-IR (KBr) νmax/ cm
-1
: 3051 (CH- aromatic), 2962 (CH- aliphatic), 1637 
(C=N), 1581(C=C); 
1
H NMR δ 2.59 (s, 3H, CH3), 2.70 (s, 3H, CH3), 3.08 (dd, J1=5.17 Hz, J2= 8.12, 1H, CH2-pyrazoline), 
3.81 (dd, J1=3.90 Hz, J2= 9.65, 1H, CH2-pyrazoline), 5.38 (dd, J1=0.87 Hz, J2= 6.88, 1H, CH-pyrazoline),  6.20 ( s, 1H, CH-
thiazole); 7.10- 8.55 (m, 15H, 14H-aromatic + 1H, CH-pyridine). Anal. Calcd. for C32H25ClN6S (561.1): C, 68.50; H, 4.49; 
Cl, 6.32; N, 14.98; S, 5.71. Found: C, 68.83; H, 4.67; Cl, 6.59;  N, 15.27; S, 5.95%. 
 
General procedure for the synthesis of 1-(1-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)ethylidene)-2-
(4-substitutedthiazol-2-yl)hydrazine (12a,b) 
A mixture of thiosemicarbazone 11 (0.001 mol), chloroacetone or phenacyl bromide (0.001 mol) in ethanol (30 mL) was 
refluxed in the presence of anhydrous sodium acetate (0.9 g, 0.011 mol) for 4 h. The solid product separated from the hot 
mixture was filtered off, washed with water and recrystallized from the proper solvent.  
 
1-(1-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)ethylidene)-2-(4-methylthiazol-2-yl)hydrazine  (12a) 
A yellow crystals (MeOH), 71%, mp 292-294ºC. FT-IR (KBr) νmax/ cm
-1
: 3290 (NH), 3060 (CH- aromatic), 2887 (CH- 
aliphatic), 1629 (C=N), 1567 (C=C); 
1
H NMR δ 1.25 (s, 3H, CH3), 2.50 (s, 3H, CH3), 2.65 (s, 3H, CH3), 3.08(s, 3H, CH3), 
6.25 ( s, 1H, CH-thiazole); 6.95- 8.45 (m, 6H, 5H-aromatic + 1H, CH-pyridine), 9.35 (s, 1H, NH, D2O-exchangeable). Anal. 
Calcd. for C20H20N6S (376.48): C, 63.81; H, 5.35; N, 22.32; S, 8.52. Found: C, 63.96; H, 5.68; N, 22.42; S, 8.83%. 
 
1-(1-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)ethylidene)-2-(4-phenylthiazol-2-yl)hydrazine (12b) 
A  yellow crystals (Acetone/H2O), 67%, mp 225-227ºC. FT-IR (KBr) νmax/ cm
-1
: 3325 (NH), 3048 (CH- aromatic), 2966 
(CH- aliphatic), 1634 (C=N), 1536 (C=C); 
1
H NMR δ 0.95 (s, 3H, CH3), 2.45 (s, 3H, CH3), 2.75 (s, 3H, CH3), 6.70 ( s, 1H, 
CH-thiazole); 7.37- 8.35 (m, 11H, 10H-aromatic + 1H, CH-pyridine), 9.15 (s, 1H, NH, D2O-exchangeable). Anal. Calcd. for 
C25H22N6S (438.55): C, 68.47; H, 5.06; N, 19.16; S, 7.32. Found: C, 68.69; H, 5.41; N, 19.36; S, 7.57%. 
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5-Methyl-5-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-1,2,4-triazolidine-3-thione (13) 
Method A 
A mixture of 11 (0.34 g, 0.001 mol) in methanol (20 mL) and hydrochloric acid (1.5 mL) was heated on the water-bath for 
30 minutes. The solid obtained after cooling was filtered off, washed with water till acid-free then crystallized from 
methanol to give compound 13as yellow crystals, 62%, mp 145-147ºC. FT-IR (KBr) νmax/ cm
-1
: 3360, 3345 and 3220 (NH), 
3050 (CH- aromatic stretch), 2980(CH- aliphatic stretch), 2720 (C=S), 1575 (C=N); 
1
H NMR δ  1.55 (s, 3H, CH3), 2.0 (s, 
1H, NH), 2.15 (s, 1H, NH), 2.25 (s, 1H, NH), 2.50 (s, 3H, CH3), 2.65 (s, 3H, CH3), 7.35- 8.20 (m, 6H, 5H-aromatic + 1H, 
CH-pyridine), Anal. Calcd. for C17H18N6S (338.47): C, 60.33; H, 5.36; N,24.83; S, 9.47. Found: C, 60.71; H, 5.59; N, 25.12; 
S, 9.68%; MS: m/z 338.19(M
+
,68). 
Method B 
A mixture 1 (0.26 g, 0.001 mol) and thiosemicarbazide (0.09g, 0.001 mole) in methanol (20 mL) and hydrochloric acid (1.5 
mL) was heated on the water-bath for 2 h. The solid obtained after cooling was filtered off, washed with water till acid-free 
then crystallized from methanol to give compound 13. All of analytical and spectral data are completely identical as 
described in method A. 
General procedure for the synthesis of 14 and 15 
A mixture of 13 (0.01 mol), 1-bromo-2-methoxyethane (0.01 mol) and K2CO3 (1.50 g) in 20 mL DMF was stirred at 75–
80°C overnight. Then, 30 mL water was added and the resulting mixture was extracted with CHCl3. The organic layer 
wasseparated, washed with water (4x30 mL), and dried over Na2SO4. After solvent evaporation, the residue was purified 
by column chromatography on silica gel using CHCl3–CH3COOCH3 (70:30)  as an eluent to afford 14 and 15.   
 
5-[5-(2-Methoxy-ethylsulfanyl)-3-methyl-3,4-dihydro-2H-[1,2,4]triazol-3-yl)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-
b]pyridine (14) 
A yellow crystals, 79%, mp 176-178ºC. FT-IR (KBr) νmax/ cm
-1
: 3405 and 3325 (NH), 3048 (CH- aromatic), 2966 (CH- 
aliphatic), 1611 (C=N) 1589 (C=C), 1226 (C-O); 
1
H NMR δ: 1.35 (s, 3H, CH3), 2.2 (s, 1H, NH), 2.40 (s, 3H, CH3), 2.65 (s, 
3H, CH3), 3.30 (s, 3H, OCH3), 3.75 (t, 2H, S-CH2), 4.15(t,2H, CH2-O), 7.20- 8.15 (m, 6H, 5H-aromatic + 1H, CH-pyridine), 
8.30 (s, 1H, NH, D2O-exchangeable); 
13
C-NMR (DMSO-d6) δ:12.30 (CH3), 14.25(CH3), 30.85 (CH3), 33.60(S-CH2), 
50.72(C), 54.26(O-CH3), 63.8 (CH2), 104.12(C), 117.81(2CH), 124.30(CH), 125.0(CH), 130.45(2CH), 135.16(CH), 
137.77(C), 139.23(C), 150.24(C), 152.0(C-S), 155.71(C); Anal. Calcd. for C20H24N6OS (396.51): C, 60.58; H, 6.10; N, 
21.20; S, 8.09%. Found: C, 60.93; H, 6.39; N, 21.42; S, 8.31%. MS: m/z 396.88(M
+
,100) 
 
5-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-2-(2-methoxy-ethyl)-5-methyl-[1,2,4]triazolidine-3-thione (15) 
A yellow crystals, 14.8%, mp 192-194ºC. FT-IR (KBr) νmax/ cm
-1
: 3390 and 3345 (N-H stretching), 3005 (C-H aromatic 
stretching), 2970 (C-H aliphatic stretching), 1600(C=C stretching), 1215(C-O, stretching): 
1
H NMR δ: 1.30 (s, 3H, CH3), 2.2 
(s, 1H, NH), 2.30 (s, 1H, NH), 2.55 (s, 3H, CH3), 2.60 (s, 3H, CH3), 3.85 (s, 3H, OCH3), 4.60 (t, 2H, N-CH2), 4.75 (t,2H, 
CH2-O), 7.30- 8.25 (m, 6H, 5H-aromatic + 1H, CH-pyridine); 
13
C-NMR (DMSO-d6) δ:11.78 (CH3), 13.95(CH3), 30.48 
(CH3), 43.34(O-CH3), 46.27(N-CH2), 50.61(C), 60.44 (CH2), 105.23(C), 115.71(2CH), 124.63(CH), 125.11(CH), 129.64 
(2CH), 133.33(CH), 137.81(C), 139.90(C), 151.11(C), 152.47(C), 172.0(C=S); Anal. Calcd. for C20H24N6OS (396.51): C, 
60.58; H, 6.10; N, 21.20; S, 8.09%. Found: C, 60.76; H, 6.42; N, 21.58; S, 8.28%. 
2-[2-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-2-methyl-6-oxo-1,2,5,6-tetrahydro-[1,3]thiazolo[3,2-
b][1,2,4]triazol-5-yl]-N-phenyl-acetamide (16) 
A mixture of 13 (0.66 g,, 0.002 mol) and N-phenylmaleimide (0.35 g, 0.02 mol) was refluxed for 2 h in glacial acetic (10 
mL). After cooling to r. t., the reaction mixture was poured into 50 mL of water. The precipitated colorless powder was 
filtered off, washed with methanol and recrystallized from ethanol to give compound 16 as yellow crystals, 65%, mp 183-
185ºC. FT-IR (KBr) νmax/ cm
-1
: 3395, 3350 (NH), 3088 (CH- aromatic), 2987(CH- aliphatic), 1710 (C=O), 1690 (C=O ), 
1585 (C=N); 
1
H NMR δ  1.40 (s, 3H, CH3), 2.15 (s, 1H, NH),  2.55 (s, 3H, CH3), 2.70 (s, 3H, CH3), 2.80 (dd, J1=3.66 Hz, 
J2= 8.70, 1H, CH2), 3.30 (dd, J1= 4.35 Hz, J2= 1.85, 1H, CH2), 4.60 (dd, J1=3.50 Hz, J2= 0.98, 1H, CH- thiazole), 7.40- 8.25 
(m, 11H, 10H-aromatic + 1H, CH-pyridine), 13.30 (s, 1H, NH);
 13
C-NMR (DMSO-d6) δ:12.55(CH3), 15.70(CH3), 
29.11(CH3), 38.65 (CH2), 48.45(CH cyclic), 69.28(C), 106.23(C), 118.09 (2CH), 120.35( 2CH), 123.15 (CH), 124.98(CH),  
128.66 (2CH), 129.64 (2CH), 130.45 (C), 137.07(C), 140.33(C), 141.72 (C), 150.51(C), 152.18(C), 159.36(C), 164.11 (C), 
173.25(C=O cyclic), 178.85 (C=O); Anal. Calcd. for C27H25N7O2S (511.60): C, 63.39; H, 4.93; N,19.16; S, 6.27. Found: C, 
63.66; H, 5.16; N, 19.38; S, 6.60%; MS: m/z 511.39(M
+
,73). 
3,6-Dimethyl-1-phenyl-5-(1,2,3-thiadiazol-4-yl)-1H-pyrazolo[3,4-b]pyridine (18) 
An excess amount of thionyl chloride (10 mL) was stirred at room temperature and the semicarbazone 17 (0.97 g, 0.003 
mol) was added in several portions. The mixtures were stirred at r.t. overnight until no more hydrogen chloride was 
produced, the product was washed with diethyl ether, dried, crystallized from benzene / pet.ether 40-60°C to afford brown 
powder of 18, 83%, mp 130-132ºC. FT-IR (KBr) νmax/ cm
-1
: 3075(CH- aromatic), 2880(CH- aliphatic), 1590 ((C=N), 
1475((C=C); 
1
H NMR δ 2.38 (s, 3H, CH3), 2.55(s, 3H, CH3), 7.20- 8.40 (m, 6H, 5H-aromatic + 1H, CH-pyridine), 9.75(s, 
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1H, CH-thiadiazole); Anal. Calcd. for C16H13N5S (307.37): C, 62.52; H, 4.26; N,22.78; S, 10.43. Found: C, 62.81; H, 4.57; 
N, 23.08; S, 10.62%; MS: m/z 307.13 (M
+
, 73). 
3,6-Dimethyl-1-phenyl-5-(1,2,3-selenadiazol-4-yl)-1H-pyrazolo[3,4-b]pyridine (19) 
The semicarbazone derivative 17 (0.97 g, 0.003 mol) was dissolved in glacial acetic acid (25 mL). To the hot solution, 
selenium dioxide powder (0.55 g, 0.005 mol) was added and the reaction mixture was stirred for 24 h. The mixture was 
filtered and the filtrates poured into ice water and extracted with CHCl3 (3×50 mL). The combined organic layers were 
washed with a saturated sodium carbonate solution, dried over anhydrous sodium sulfate. After evaporation of the solvent 
the residue was crystallized from toluene to give brown powder of 19, 74%, mp 112-114ºC. FT-IR (KBr) νmax/ cm
-1
: 
3007(CH- aromatic), 2985(CH- aliphatic), 1595 (C=N), 1480((C=C), 820 (C-Se-N); 
1
H NMR δ 2.45 (s, 3H, CH3), 2.61(s, 
3H, CH3), 7.33- 8.29 (m, 6H, 5H-aromatic + 1H, CH-pyridine), 10.12(s, 1H, CH-selenadiazole); Anal. Calcd. for 
C16H13N5Se (354.27): C, 54.24; H, 3.70; N,19.77%. Found: C, 54.60; H, 3.92; N, 20.11; MS: m/z 354.19 (M
+
, 56). 
3-Hydroxy-3-(2-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-2-oxoethyl)indolin-2-one (20). 
To a solid homogenous mixture of 1 (0.52 g, 0.002 mol) and  isatine (0.3 g, 0.002 mol), 10 drops of dimethylamine was 
added and the mixture stirred for 15-30 minutes and a colorless solid formed was recrystallized from ethanol to give buff 
powder of 20, 61%, mp 191-193ºC. FT-IR (KBr) νmax/ cm
-1
: 3500 (OH), 3410 (NH), 3080(CH- aromatic), 2970(CH 
aliphatic), 1705(C=O), 1630(C=O) 1580(C=N), 1465(C=C); 
1
H NMR δ 2.20 (s, 1H, OH), 2.50 (s, 3H, CH3), 2.70(s, 3H, 
CH3), 3.15 (s, 2H, CH2), 7.35- 8.40 (m, 10H, 9H-aromatic + 1H, CH-pyridine), 8.60 (s, 1H, NH); Anal. Calcd. for 
C24H20N4O3 (412.44): C, 69.89; H, 4.89; N,13.58%. Found: C, 70.27; H, 4.95; N, 13.83. 
3-(2-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-2-oxoethylidene)indolin-2-one (21). 
A mixture of 20 (0.4g, 0.001 mol), ethanol 25 mL and 40 mL of dilute HCl solution (25%), was allowed to stand overnight, 
fine orange needles were formed and recrystallized from ethanol to give buff powder of 21, 69%, mp 210-212ºC. FT-IR 
(KBr) νmax/ cm
-1
: 3395 (NH), 3087(CH-aromatic), 2990(CH- aliphatic), 1675(C=O), 1630(C=O) , 1565(C=N ), 1480(C=C) ; 
1
H NMR δ 2.55 (s, 3H, CH3), 2 .68(s, 3H, CH3), 7.28- 8.55 (m, 11H, 10H-aromatic + 1H, CH-pyridine), 8.70 (s, 1H, NH); 
Anal. Calcd. for C24H18N4O2 (394.43): C, 73.08; H, 4.60; N,14.20%. Found: C, 73.31; H, 4.93; N, 14.54%. 
5-′(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-2′ , 4′-dihydrospiro[indol-3,3′-pyrazol]-2-(1H)-one (22). 
Method A 
A mixture of 21 ( 0.4 g, 0.001 mol) and hydrazine hydrate (0.20 mL) in ethanol  (25 mL) was heated under reflux for 4 h, 
then left to cool, the residual material was filtered off and recrystallized from ethanol to afford yellow crystals of 22, 71%, 
mp 211-213ºC. FT-IR (KBr) νmax/ cm
-1
: 3420, 3365 (NH), 3069(CH- aromatic), 2877(CH- aliphatic) , 1646(C=O), 
1570(C=N), 1473(C=C); 
1
H NMR δ 2.60 (s, 3H, CH3), 2 .70(s, 3H, CH3), 3.60 (s, 2H, CH2), 6.30 (s, 1H, NH), 7.35- 8.48 
(m, 10H, 9H-aromatic + 1H, CH-pyridine), 8.63(s, 1H, NH); Anal. Calcd. for C24H20N6O (408.46): C, 70.57; H, 4.94; 
N,20.58%. Found: C, 70.84; H, 5.11; N, 20.79%. MS: m/z 408.30 (M
+
, 82). 
Method B. 
To a mixture of 1 (0.52 g, 0.002 mol ) and isatin (0.3 g, 0.002 mol) and, dimethylamine (5 drops) was added and the 
mixture was stirred for 30 min at room temperature. To the formed solid, glacial acetic acid (10 mL) and concentrated 
hydrochloric acid (3 drops) were added and the reaction mixture was heated at 80 ºC for 30 min. Hydrazine hydrate (0.02 
mol) was added to the previous reaction mixture and heating was continued at 80 ºC for 1 h to give spiro compound 22. 
The product was identical with that formed by method A. 
5-′(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-2′ -phenyl-4′-dihydrospiro[indol-3,3′-pyrazol]-2-(1H)-one 
(23) 
A mixture of 21 ( 0.4 g, 0.001 mol) and  phenyl hydrazine (0.5 mL) in ethanol  (25 mL) was heated under reflux for 7 h, 
then left to cool, the residual material was filtered off and recrystallized from ethanol to afford yellow crystals of 23, 63%, 
mp 320-322ºC. FT-IR (KBr) νmax/ cm
-1
: 3087(CH-aromatic), 2889(CH- aliphatic), 1650(C=O), 1565(C=N), 1482(C=C); 
1
H 
NMR δ 2.64 (s, 3H, CH3), 2.75(s, 3H, CH3), 3.49 (s, 2H, CH2), 7.25- 8.51 (m, 15H, 14H-aromatic + 1H, CH-pyridine), 8.60 
(s, 1H, NH); Anal. Calcd. for C30H24N6O (484.55): C, 74.36; H, 4.99; N,17.34%. Found: C, 70.55; H, 5.23; N, 17.70%. 
3′-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)- 4′-dihydrospiro[indol-3,5′-isoxazole]-2-(1H)-one (24). 
A mixture of compound 21 (0.4 g, 0.001 mol), hydroxylamine hydrochloride (0.14 g, 0.002 mol) and anhydrous sodium 
acetate (0.085 g, 0.003 mol) in absolute ethanol (10 mL) was refluxed for 6 h. After cooling, the reaction mixture was 
poured onto ice-water (50 mL). The solid that formed was filtered off, air dried and recrystallized from absolute ethanol to 
afford white crystals of 24, 66%, mp 273-275ºC. FT-IR (KBr) νmax/ cm
-1
: 3090(CH- aromatic), 2880(CH- aliphatic), 
1655(C=O) , 1560(C=N), 1460(C=C) 1250 (C-O-N ); 
1
H NMR δ 2.66 (s, 3H, CH3), 2.79(s, 3H, CH3), 3.25 (s, 2H, CH2), 
7.25- 8.45 (m, 10H, 9H-aromatic + 1H, CH-pyridine), 8.65 (s, 1H, NH); Anal. Calcd. for C24H19N5O2 (409.44): C, 70.40; H, 
4.68; N,17.10%. Found: C, 70.73; H, 4.92; N, 17.50%. 
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6′-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)- spiro[indol-3,4′ -pyrimidin-2′- (1H) thione]-2-(1H)-one 
 (25). 
A mixture of chalcone  21(0.4 g, 0.001 mol), thiourea (0.076 g, 0.001 mol) and potassium hydroxide (1.0 g) in ethanol (40 
ml) was refluxed on a boiling water bath for one hour. The reaction mixture was left overnight and then concentrated under 
reduced pressure. The solid residue was collected, washed with water and recrystallized from ethanol to yield yellow 
crystals of 25, 68%, mp 172-174ºC. FT-IR (KBr) νmax/ cm
-1
: 3340, 3210, 3180 (NH), 3085(CH- aromatic), 2890(CH- 
aliphatic), 1645(C=O) , 1555(C=N), 1490(C=C) 1180 (C=S ); 
1
H NMR δ 2.55 (s, 3H, CH3), 2.75(s, 3H, CH3), 6.20 (s, 1H, 
CH-pyrimidine), 7.15- 8.35 (m, 10H, 9H-aromatic + 1H, CH-pyridine), 8.65(s, 1H, NH), 8.85 (s,br, 1H, NH), 9.90 (s, br, 1H, 
NH); Anal. Calcd. for C25H20N6OS (452.53): C, 66.35; H, 4.45; N,18.57; S, 7.09%. Found: C, 66.59; H, 4.78; N, 18.88; S, 
7.32%. 
2-Cyano-N'-[1-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-ethylidene]acetocarbohydrazide (26) 
To a solution of cyanoacetylhydrazine ( 0.99 g, 0.001 mol) in 1,4-dioxane (20 mL), compound 1 (0.26 g, 0.001 mol) was 
added. The reaction  mixture was heated under reflux for 4 h then poured onto a beaker containing an ice/water mixture. 
The formed solid product was collected by filtration and recrystallized from ethanol to give white crystals 0f 26, 68%, mp 
209-211ºC. FT-IR (KBr) νmax/ cm
-1
: 3365(NH), 3090(CH-aromatic), 2880(CH-aliphatic), 2245 (CN), 1679(C=O), 
1570(C=N), 1475(C=C); 
1
H NMR δ 1.90 (s, 3H, CH3), 2.40 (s, 3H, CH3), 2.78(s, 3H, CH3), 4.40 (s, 2H, CH2),7.26- 8.30 (m, 
6H, 5H-aromatic + 1H, CH-pyridine); Anal. Calcd. for C19H18N6O (346.39): C, 65.88; H, 5.24; N, 24.26%. Found: C, 66.13; 
H, 5.49; N, 24.60%; 
13
C-NMR (DMSO-d6) δ:11.95 (CH3), 12.80(CH3), 15.60(CH3), 26.80(CH2), 105.79(C), 113.64 (CN), 
118.50(2CH), 124.91(C), 126.11(C), 128.76(2CH), 132.81(C), 136.34(CH), 138.13(C), 150.41(C), 156.37(C), 158.22(C),  
174.19 (C=O); MS: m/z 346.54 (M
+
, 62). 
3-(4-Chlorophenyl)-2-cyano-N'-[1-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-ethylidene]acrylo-
hydrazide (27) 
To a solution of 26 (0.35 g, 0.001 mol) in 1,4-dioxane (20 mL), p-chlorobenzaldehyde (0.14 g, 0.001 mol)  was added. The 
reaction mixture was heated under reflux for 6 h then poured onto a beaker containing an ice/water mixture. The formed 
solid product was collected by filtration and and recrystallized from ethanol to give white crystals of 27, 60%, mp 103-
105ºC. FT-IR (KBr) νmax/ cm
-1
: 3345(NH), 3087(CH- aromatic), 2969(CH- aliphatic), 2238 (CN), 1660(C=O), 1620(C=N), 
1498(C=C); 
1
H NMR δ 1.65 (s, 3H, CH3), 2.55 (s, 3H, CH3), 2.65(s, 3H, CH3), 7.17- 8.33 (m, 11H, 9H-aromatic + 1H, CH-
pyridine + 1 H, C=CH); Anal. Calcd. for C26H21ClN6O (468.94):C, 66.59; H, 4.51;Cl, 7.56; N, 17.92%. Found: C, 66.81; H, 
4.79; Cl, 7.83; N, 18.16%.  
2-Oxo-N'-[1-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-ethylidene]-2H-chromene-3-carbohydrazide 
(28) 
To a solution of 26 (0.35 g, 0.001 mol) in 1,4-dioxane (20 mL), salicylaldehyde (0.12 g, 0.001 mol) was added. The 
reaction mixture was heated under reflux for 5 h then poured onto a beaker containing an ice/water mixture. The formed 
solid product was collected by filtration and and recrystallized from ethanol to give white crystals of 28, 64%, mp 216-
218ºC. FT-IR (KBr) νmax/ cm
-1
: 3368(NH), 3080(CH-aromatic), 2943(CH- aliphatic), 1670(C=O), 1650(C=N), 1490(C=C); 
1
H NMR δ 1.83 (s, 3H, CH3), 2.50 (s, 3H, CH3), 2.66(s, 3H, CH3), 7.20- 8.35 (m, 11H, 10H-aromatic + 1H, CH-pyridine), 
8.72 (s, 1H, CH-Coumarin); Anal. Calcd. for C26H21N5O3 (451.48):C, 69.17; H, 4.69; N, 15.51%. Found: C, 69.33; H, 4.75; 
N, 15.77%. 
4-Amino-1-[1-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-yl)-ethylideneamino]-2oxo-4-phenyl-1,2-dihydro 
pyridine-3,5-dicarbonitrile (29) 
To a solution of 26 (0.35 g, 0.001 mol) in 1,4-dioxane (20 mL), 2-benzylidenemalononitrile (0.15 g, 0.001 mol) was added. 
The reaction mixture was heated under reflux for 6 h then poured onto a beaker containing an ice/water mixture. The 
formed solid product was collected by filtration and and recrystallized from ethanol to give pale yellow crystals of 29, 77%, 
mp 324-326ºC. FT-IR (KBr) νmax/ cm
-1
: 3452, 3368(NH2), 3095(CH- aromatic), 2971(CH- aliphatic),2229, 2189 (2CN), 
1665(C=O), 1641(C=N), 1488(C=C); 
1
H NMR δ 2.11 (s, 3H, CH3), 2.57 (s, 3H, CH3), 2.64(s, 3H, CH3), 3.87 (s, 2H, NH2), 
7.27- 8.48 (m, 11H, 10H-aromatic + 1H, CH-pyridine); Anal. Calcd. for C29H22N8O (498.54):C, 69.87; H, 4.45; N, 22.48%. 
Found: C, 70.19; H, 4.58; N, 22.65%. 
ANTIMICROBIAL ACTIVITY 
The antimicrobial activity of 22 selected compounds was screened against bacterial strains Staphylococcus aureus 
(AUMC B.54),  Bacillus cereus (AUMC B.52) as gram-positive bacteria and  Escherichia coli (AUMC B.53), Pseudomonas 
aeruginosa (AUMC B.73) as gram-negative bacteria and fungal strains Candida albicans (AUMC No.214), Aspergillus 
flavus (AUMC No.1276) using the agar well-diffusion method. 
31
 all  microbial  strains  were  kindly  provided  by  the  
Assiut University  Mycological  Centre  (AUMC).  To  prepare  inocula  for bioassay, bacterial strains were individually 
cultured for 48 h in 100 mL  conical  flasks  containing  30  mL  nutrient  broth  medium.  Fungi were  grown  for  7  days  in  
100  mL  conicals  containing 30  mL Sabouraud's  dextrose  broth.  Bioassay  was  done  in  10 cm  sterile plastic Petri 
plates in which microbial suspension (1 mL/plate) and 15  mL  appropriate  agar  medium  (15  mL/plate)  were  poured. 
Nutrient agar and Sabouraud's dextrose agar were respectively used for bacteria and fungi.  After  solidification  of  the 
media,  5  mm diameter  cavities  were  cut  in  the  solidified  agar  (4  cavities/plate) using sterile cork borer. Chemical 
compounds dissolved in DMSO at 2%w/v  (=20  mg/mL)  were pipetted  in  the  cavities.  The screening tests were carried 
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out in triplicate and the results were expressed as a mean of three determinations. Chloramphenicol and Clotrimazole 
were used as standards. Data are represented as % inhibition with reference to standards in (Table1). 
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